David Olson

David Olson, director at UC Davis Institute for Psychedelics and co-founder of Delix Therapeutics, delves into groundbreaking research on non-hallucinogenic drugs that promote neuroplasticity. He discusses how these substances may treat depression and anxiety while avoiding the psychedelic ‘trip.’ Olson also explores design challenges in creating these therapies, including safety and abuse potential. He outlines encouraging results from clinical trials on zalzupindol, highlighting rapid antidepressant effects that last well beyond treatment.

David Olson, a neuroscientist pioneering non-hallucinogenic treatments, joins psychiatrist Charles Raison and retired psychologist Rachel Harris to explore the dual nature of psychedelics in mental health. They debate whether profound experiences or molecular changes drive healing. The trio discusses the evolution of psychiatric practices, the potential of psychedelics versus traditional antidepressants, and the spiritual wisdom from underground healers. Engaging personal stories reveal the transformative power of psychedelics and the importance of women's voices in this burgeoning field.